{
    "Trade/Device Name(s)": [
        "Lyra Influenza A + B Assay"
    ],
    "Submitter Information": "Quidel Corporation",
    "510(k) Number": "K230236",
    "Predicate Device Reference 510(k) Number(s)": [
        "K131728"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OZE",
        "OOI"
    ],
    "Summary Letter Date": "January 27, 2023",
    "Summary Letter Received Date": "January 30, 2023",
    "Submission Date": "January 27, 2023",
    "Regulation Number(s)": [
        "21 CFR 866.3980",
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Respiratory Viral Panel Multiplex Nucleic Acid Assay",
        "Real Time Nucleic Acid Amplification System"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology"
    ],
    "Analyte(s)": [
        "Influenza A virus RNA",
        "Influenza B virus RNA"
    ],
    "Specimen Type(s)": [
        "Nasal swab",
        "Nasopharyngeal swab"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Life Technologies QuantStudio Dx",
        "Applied Biosystems 7500 Fast Dx",
        "Cepheid SmartCycler II"
    ],
    "Method(s)/Technology(ies)": [
        "Multiplex Real Time RT-PCR",
        "Nucleic acid extraction"
    ],
    "Methodologies": [
        "RT-PCR",
        "Multiplex PCR"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Quidel Lyra Influenza A + B multiplex RT-PCR assay for qualitative detection and differentiation of influenza A and B viral RNA in respiratory swabs",
    "Indications for Use Summary": "A multiplex RT-PCR assay for in vitro qualitative detection and differentiation of influenza A and B viral RNA in nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the differential diagnosis of influenza A and B viral infections in humans.",
    "fda_folder": "Microbiology"
}